ATE516306T1 - Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen - Google Patents

Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen

Info

Publication number
ATE516306T1
ATE516306T1 AT04700825T AT04700825T ATE516306T1 AT E516306 T1 ATE516306 T1 AT E516306T1 AT 04700825 T AT04700825 T AT 04700825T AT 04700825 T AT04700825 T AT 04700825T AT E516306 T1 ATE516306 T1 AT E516306T1
Authority
AT
Austria
Prior art keywords
tfpi
chromatography
analog
sepharose
concentration
Prior art date
Application number
AT04700825T
Other languages
English (en)
Inventor
David H Reifsnyder
Duane Inlow
Glen Dorin
Patricio T Riquelme
Cynthia Cowgill
Doug G Bolesch
Mark E Gustafson
Original Assignee
Novartis Vaccines & Diagnostic
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Pharmacia & Upjohn Co Llc filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE516306T1 publication Critical patent/ATE516306T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
AT04700825T 2003-08-13 2004-01-08 Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen ATE516306T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49454603P 2003-08-13 2003-08-13
US50927703P 2003-10-08 2003-10-08
US51219903P 2003-10-20 2003-10-20
PCT/US2004/000234 WO2005019265A1 (en) 2003-08-13 2004-01-08 Improved method of purifying tfpi and tfpi analogs

Publications (1)

Publication Number Publication Date
ATE516306T1 true ATE516306T1 (de) 2011-07-15

Family

ID=34222354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04700825T ATE516306T1 (de) 2003-08-13 2004-01-08 Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen

Country Status (6)

Country Link
US (1) US7851433B2 (de)
EP (1) EP1654283B1 (de)
JP (2) JP4522997B2 (de)
AT (1) ATE516306T1 (de)
CA (1) CA2535562A1 (de)
WO (1) WO2005019265A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1602667B1 (de) * 1995-06-07 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Waessrige Formulierung enthaltend TFPI und Lösungsvermittlers
EP1654283B1 (de) * 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
AU2006244053A1 (en) * 2005-05-06 2006-11-16 Novartis Ag Use of TFPI to treat severe bacterial infections
EP1996697A2 (de) * 2006-03-07 2008-12-03 Novartis AG Verhinderung von norvalin- und norleucin-fehlinkorporation in rekombinante proteine
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2025120204A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
EP0325691B1 (de) * 1988-01-25 1993-04-07 Consortium für elektrochemische Industrie GmbH Verfahren zur Solubilisierung von unlöslichem Protein
EP0414374B1 (de) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigene sowie Verfahren zu deren Herstellung
DK0473564T3 (da) 1990-08-27 1996-04-15 Monsanto Co Antikoagulant kombination af LACI og sulfatiserede polysaccharider
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
WO1993024143A1 (en) 1992-06-01 1993-12-09 Cetus Oncology Corporation A method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU4408493A (en) 1992-06-11 1994-01-04 Washington University Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IL113497A0 (en) 1994-04-28 1995-07-31 Amgen Inc Method for controlling metallophosphate precipitation in high cell density fermentations
ATE229978T1 (de) 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
WO1996001649A1 (en) 1994-07-07 1996-01-25 Washington University Method of attenuating arterial stenosis
JP3779728B2 (ja) * 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
EP1602667B1 (de) 1995-06-07 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Waessrige Formulierung enthaltend TFPI und Lösungsvermittlers
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
WO1996040224A1 (en) 1995-06-07 1996-12-19 Chiron Corporation Regulation of cytokine synthesis and release
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
CA2463655A1 (en) 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP1654283B1 (de) * 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen

Also Published As

Publication number Publication date
US20050037475A1 (en) 2005-02-17
JP2007528211A (ja) 2007-10-11
US7851433B2 (en) 2010-12-14
JP2010031055A (ja) 2010-02-12
WO2005019265A1 (en) 2005-03-03
EP1654283A1 (de) 2006-05-10
CA2535562A1 (en) 2005-03-03
EP1654283B1 (de) 2011-07-13
JP4522997B2 (ja) 2010-08-11

Similar Documents

Publication Publication Date Title
NO20061026L (no) Nye insulinderivater
ATE516306T1 (de) Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
ATE408624T1 (de) Verfahren zur reinigung von fsh
ATE541582T1 (de) Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
ATE446313T1 (de) Muteine von tränen-lipocalin
BG103694A (bg) Метод за получаване и пречистване на n- алкилирано аспарагиново производно
SE0301010D0 (sv) Novel compounds
ATE361313T1 (de) Allgemeines verfahren zur rückfaltung rekombinanter proteine
ATE349460T1 (de) Rückfaltung von protein-aggregaten und einschlussteilchen durch hohen druck
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
EP0134479A1 (de) Modifizierte Protease-Inhibitoren, Verfahren zu ihrer Herstellung und daraus bereitete pharmazeutische Mittel
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE3686954D1 (de) Loeslichkeits-, reinigungs- und charakterisierungsverfahren fuer proteine aus unloeslichen proteinaggregaten oder proteinkomplexen und diesbezuegliche praeparate.
DE170917T1 (de) Neues derivat des humangammainterferon-polypeptids.
ATE381945T1 (de) Verfahren zur solubilisierung von peptid- mischungen
DE502004003404D1 (de) Verfahren zur reinigung von dimethylacetamid (dmac)
WO2004026891A3 (en) Protein purification
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
DE602004004156D1 (de) Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
ATE404577T1 (de) Verfahren zur herstellung von eplerenon
DE60034117D1 (de) Verfahren zur herstelllung von gonadotropin-zusammensetzungen
DE602004017448D1 (de) Verfahren zur tensid-quantifizierung eines proteinpräparates
ATE447584T1 (de) Verfahren zur gewinnung von biologisch aktivem humanen g-csf aus inclusion bodies
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
ATE175975T1 (de) Verdrängungschromatographisches verfahren und gereinigtes hämoglobin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties